Biosense Webster, Inc., the worldwide leader in the diagnosis and
treatment of cardiac arrhythmias, announced today the execution of
strategic collaboration agreements with two leading global imaging
companies, GE Healthcare and Siemens Healthcare.
The announcement was made during the Heart Rhythm Society's (HRS) 33rd
Annual Scientific Sessions. HRS 2012, the largest global conference for
electrophysiologists, is being held in Boston from May 9-12, 2012.
Biosense Webster, Inc. has developed an image integration solution for
electrophysiology (EP) labs around the world. This solution integrates
real-time x-ray images, from Siemens Healthcare and GE Healthcare X-Ray
systems, into the company's market leading CARTO® 3, 3D
Electroanatomical Mapping & Ablation System. Under the terms of the two
agreements, Biosense Webster, Inc. plans to offer an integrated
solution, compatible with both manufacturers' fluoroscopy systems, in
"Minimizing x-ray exposure for patients and clinicians has long been a
focus of healthcare technology manufacturers," said Shlomi Nachman,
Worldwide President, Cardiovascular Care franchise. "These two important
strategic agreements will allow Biosense Webster to address the growing
need to combine multiple images from different systems in the EP lab
into a single display on our CARTO® 3 System."
These latest agreements mark a significant step towards Biosense
Webster, Inc.'s vision of providing a comprehensive integrated lab
solution to electrophysiologists and hospitals around the world. GE
Healthcare and Siemens Healthcare collectively, represent over 50% of
the installed base of X-Ray systems across the globe.
"These strategic collaborations and the resulting technology
advancements, continue our commitment to bringing innovation to the
Cardiac Electrophysiology community so they may better serve their
patients and protect themselves," said Nachman.
About AF and cardiac ablation
Atrial Fibrillation is the most prevalent arrhythmia, and is a leading
cause of stroke among people 65 years and older. Worldwide, it is
estimated that 20 million people have AF, yet only approximately 130,000
are treated with ablation every year. The public health implications of
AF are a growing concern because those with AF are at an increased risk
of morbidity and mortality as well as a reduced quality of life.
Most patients with AF today are treated with anti-arrhythmic drugs
(AADs), even though about half of them are refractory to these drugs.
During cardiac ablation, energy is delivered through the catheter to
those areas of the heart muscle causing the abnormal heart rhythm. This
energy "disconnects" the pathway of the abnormal rhythm. Cardiac
ablation is a very common treatment for "simple" arrhythmias, like
Wolff-Parkison-White Syndrome and atrioventricular nodal re-entry
tachycardia (AVNRT), and is increasingly being used for more complex
arrhythmias like ventricular tachycardia and atrial fibrillation. In the
US, ThermoCool® Navigation Catheters are approved for drug refractory
recurrent symptomatic paroxysmal atrial fibrillation, when used with
CARTO® Systems (excluding NAVISTAR® RMT THERMOCOOL® Catheter).
About Biosense Webster, Inc.
Biosense Webster, Inc., pioneered EP diagnostic catheters more than 20
years ago and continues to lead the industry as an innovative provider
of advanced diagnostic, therapeutic, and mapping tools. As the leader in
navigation systems and ablation therapy, Biosense Webster, Inc. has
technology that includes the largest installed base of navigation
systems worldwide in leading hospitals and teaching institutions. For
more information about Biosense Webster and its products, please visit: www.biosensewebster.com
(this site is intended for US visitors only).
This press release contains "forward-looking statements" as defined in
the Private Securities Litigation Reform Act of 1995. The reader is
cautioned not to rely on these forward-looking statements. These
statements are based on current expectations of future events. If
underlying assumptions prove inaccurate or unknown risks or
uncertainties materialize, actual results could vary materially from the
expectations and projections of Biosense Webster, Inc. and/or Johnson &
Johnson. Risks and uncertainties include, but are not limited to,
general industry conditions and competition; economic factors, such as
interest rate and currency exchange rate fluctuations; technological
advances, new products and patents attained by competitors; challenges
inherent in new product development, including obtaining regulatory
approvals; challenges to patents; changes in behavior and spending
patterns or financial distress of purchasers of health care products and
services; changes to governmental laws and regulations and domestic and
foreign health care reforms; trends toward health care cost containment;
and increased scrutiny of the health care industry by government
agencies. A further list and description of these risks, uncertainties
and other factors can be found in Exhibit 99 of Johnson & Johnson's
Annual Report on Form 10-K for the fiscal year ended January 1, 2012.
Copies of this Form 10-K, as well as subsequent filings, are available
online at www.sec.gov,
or on request from Johnson & Johnson. Neither Biosense Webster, Inc. nor
Johnson & Johnson undertake to update any forward-looking statements as
a result of new information or future events or developments.
For Biosense Webster, Inc.
Sandra Pound, 908-218-2720